Form 4 for REVB REVELATION BIOSCIENCES, INC.
Accepted 2025-10-31 00:00:00 ET · period of report 2025-10-29 · accession 0001193125-25-260423 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-31 | 2025-10-29 | REVB | Rolke James | CEO, Dir | A - Grant | $1.28 | +390.6K | 400.7K | +3,888% | +$500.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-29 | A | A | 390,614 | $1.28 | 400,660 | D | — | — | (F1) Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the grant date. |